Spain · Delayed Price · Currency is EUR Vytrus Biotech Statistics
Total Valuation
Vytrus Biotech has a market cap or net worth of EUR 113.12 million. The enterprise value is 110.92 million.
| Market Cap | 113.12M |
| Enterprise Value | 110.92M |
Important Dates
The next estimated earnings date is Thursday, March 25, 2027.
| Earnings Date | Mar 25, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Vytrus Biotech has 7.52 million shares outstanding. The number of shares has decreased by -0.10% in one year.
| Current Share Class | 7.52M |
| Shares Outstanding | 7.52M |
| Shares Change (YoY) | -0.10% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.94% |
| Owned by Institutions (%) | 16.27% |
| Float | 3.77M |
Valuation Ratios
The trailing PE ratio is 39.05.
| PE Ratio | 39.05 |
| Forward PE | n/a |
| PS Ratio | 11.67 |
| PB Ratio | 10.97 |
| P/TBV Ratio | 21.13 |
| P/FCF Ratio | 39.19 |
| P/OCF Ratio | 29.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.70, with an EV/FCF ratio of 38.43.
| EV / Earnings | 38.29 |
| EV / Sales | 11.44 |
| EV / EBITDA | 32.70 |
| EV / EBIT | 35.15 |
| EV / FCF | 38.43 |
Financial Position
The company has a current ratio of 3.03, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.03 |
| Quick Ratio | 2.67 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.37 |
| Debt / FCF | 0.43 |
| Interest Coverage | 37.71 |
Financial Efficiency
Return on equity (ROE) is 32.91% and return on invested capital (ROIC) is 36.07%.
| Return on Equity (ROE) | 32.91% |
| Return on Assets (ROA) | 15.29% |
| Return on Invested Capital (ROIC) | 36.07% |
| Return on Capital Employed (ROCE) | 24.49% |
| Weighted Average Cost of Capital (WACC) | 3.81% |
| Revenue Per Employee | 220,285 |
| Profits Per Employee | 65,833 |
| Employee Count | 44 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.47 |
Taxes
In the past 12 months, Vytrus Biotech has paid 229,300 in taxes.
| Income Tax | 229,300 |
| Effective Tax Rate | 7.34% |
Stock Price Statistics
The stock price has increased by +159.48% in the last 52 weeks. The beta is -0.08, so Vytrus Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | +159.48% |
| 50-Day Moving Average | 16.48 |
| 200-Day Moving Average | 15.16 |
| Relative Strength Index (RSI) | 28.24 |
| Average Volume (20 Days) | 1,807 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vytrus Biotech had revenue of EUR 9.69 million and earned 2.90 million in profits. Earnings per share was 0.39.
| Revenue | 9.69M |
| Gross Profit | 8.83M |
| Operating Income | 3.16M |
| Pretax Income | 3.13M |
| Net Income | 2.90M |
| EBITDA | 3.39M |
| EBIT | 3.16M |
| Earnings Per Share (EPS) | 0.39 |
Balance Sheet
The company has 3.44 million in cash and 1.24 million in debt, with a net cash position of 2.20 million or 0.29 per share.
| Cash & Cash Equivalents | 3.44M |
| Total Debt | 1.24M |
| Net Cash | 2.20M |
| Net Cash Per Share | 0.29 |
| Equity (Book Value) | 10.31M |
| Book Value Per Share | 1.37 |
| Working Capital | 3.61M |
Cash Flow
In the last 12 months, operating cash flow was 3.90 million and capital expenditures -1.01 million, giving a free cash flow of 2.89 million.
| Operating Cash Flow | 3.90M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 236,628 |
| Net Borrowing | -470,209 |
| Free Cash Flow | 2.89M |
| FCF Per Share | 0.38 |
Margins
Gross margin is 91.10%, with operating and profit margins of 32.56% and 29.89%.
| Gross Margin | 91.10% |
| Operating Margin | 32.56% |
| Pretax Margin | 32.25% |
| Profit Margin | 29.89% |
| EBITDA Margin | 35.00% |
| EBIT Margin | 32.56% |
| FCF Margin | 29.78% |
Dividends & Yields
Vytrus Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.10% |
| Shareholder Yield | 0.10% |
| Earnings Yield | 2.56% |
| FCF Yield | 2.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vytrus Biotech has an Altman Z-Score of 6.92 and a Piotroski F-Score of 8.
| Altman Z-Score | 6.92 |
| Piotroski F-Score | 8 |